Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
Gilead Sciences(GILD) stock is priced at $176.43, giving the company a market capitalization of 218.83B. It carries a P/E multiple of -55.42 and pays a dividend yield of 1.86%.
During the trading session on 2026-11-05, Gilead Sciences(GILD) shares reached a daily high of $177.18 and a low of $173.92. At a current price of $176.43, the stock is +1.4% higher than the low and still -0.4% under the high.
Trading activity shows a volume of 968.32K, compared to an average daily volume of 7.32M.
The stock's 52-week range extends from a low of $116.88 to a high of $177.18.
The stock's 52-week range extends from a low of $116.88 to a high of $177.18.
GILD News
Gilead Sciences (NasdaqGS:GILD) and Kite reported new CAR T cell therapy data for blood cancers at the 2026 ASH Annual Meeting. The update included 18 month fo...
Gilead Sciences (GILD +4.19%) is the leading pharmaceutical company that produces HIV treatments. Its chronic HIV management therapies are largely insulated fro...
Gilead Sciences (GILD) announced an update on their ongoing clinical study. Study Overview: Gilead Sciences is studying GS-1206 in adults with solid tumors und...
Analyst ratings
77%
of 30 ratingsMore GILD News
Gilead Sciences (GILD Quick QuoteGILD - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review...
Gilead Sciences (GILD) just turned a strong third quarter into a louder statement. An earnings beat linked to HIV treatments, a higher HIV growth outlook and a...
has delivered a very strong run over the past few years, which puts a bright spotlight on whether the current share price lines up with the cash the business is...
Gilead Sciences reported third quarter 2026 revenue of US$8.3b with earnings above market expectations, raised full year product sales guidance, and highlighted...
Gilead Sciences stock came into Friday already on a tear, with a 90 day gain above 30%, then tacked on another 3.1% after the Q3 2026 release as traders rushed...
Gilead Sciences, Inc. (NASDAQ:GILD) reported better-than-expected earnings for the third quarter on Thursday. The company posted quarterly earnings of $2.55 pe...
For the quarter ended September 2026, Gilead Sciences (GILD Quick QuoteGILD - Free Report) reported revenue of $8.3 billion, up 6.8% over the same period...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.